Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company developing cancer therapies based on PLK1 inhibition, with its lead asset onvansertib in multiple clinical programs. The CRDF news page on Stock Titan aggregates company announcements, clinical data updates, financial results and investor event participation so readers can follow how the onvansertib development story evolves over time.
News coverage for Cardiff Oncology frequently highlights clinical trial milestones, such as enrollment completion and data readouts from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer. Press releases also describe results from investigator-initiated studies, including onvansertib in combination with paclitaxel in metastatic triple negative breast cancer and monotherapy use in chronic myelomonocytic leukemia, as well as data presented at major scientific meetings like ASCO and ASH.
Investors and observers can also find quarterly financial results and business updates, where Cardiff Oncology reports on research and development spending, cash runway and key operational highlights, alongside commentary on the progress of onvansertib across different tumor types. In addition, the company regularly announces participation in healthcare and investor conferences, including fireside chats, corporate presentations and one-on-one meetings hosted by firms such as Piper Sandler, Guggenheim, Stifel, Wells Fargo, Morgan Stanley and others.
This news feed offers a centralized view of Cardiff Oncology’s disclosures, from clinical efficacy and safety data to patent developments and leadership changes. Readers interested in oncology drug development, PLK1 inhibition, or the CRDF ticker can use this page to track Cardiff Oncology’s ongoing activities and key communications to the market.
Cardiff Oncology (Nasdaq: CRDF) will host a key opinion leader webinar on April 30, 2026 at 11:00 a.m. ET to discuss investigator-initiated trial data showing single-agent activity of onvansertib in chronic myelomonocytic leukemia (CMML).
Registration and live webcast access are available via the company Events page; a replay will be posted after the discussion.
Cardiff Oncology (Nasdaq: CRDF) will present updated Phase 2 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) at ASCO 2026. The rapid oral presentation (Abstract #3510) is scheduled for June 2, 2026, 8:00-9:30 AM CDT.
The abstract will be publicly available May 21, 2026, and the presentation will be posted on the company’s Scientific Publications page after ASCO.
Cardiff Oncology (Nasdaq: CRDF) will present preclinical poster data at AACR 2026 showing its oral PLK1 inhibitor onvansertib potentiates trastuzumab deruxtecan (T-DXd) in HER2-low breast cancer models.
The combination produced tumor regression in nearly all mice, with complete responses up to 62%, synergistic cell‑kill in resistant lines, extended event‑free survival, and favorable tolerability. Poster available April 19, 2026; online after presentation.
Cardiff Oncology (Nasdaq: CRDF) appointed Mani Mohindru, PhD, as President and Chief Executive Officer and named Josh Muntner as Chief Financial Officer (effective April 6, 2026) and Ajay Aggarwal, MD, MBA, as Chief Operating Officer (effective April 27, 2026).
Leadership hires aim to advance onvansertib in first-line RAS-mutant metastatic colorectal cancer. The company granted Mr. Muntner a non‑qualified option for 486,650 shares at an exercise price of $1.58, vesting over four years under Nasdaq inducement rule 5635(c)(4).
Cardiff Oncology (Nasdaq: CRDF) will host a key opinion leader webinar on March 25, 2026 at 4:30 p.m. ET focused on first-line RAS-mutated metastatic colorectal cancer (mCRC).
The session features KOLs Scott Kopetz, M.D., Ph.D., Heinz-Josef Lenz, M.D., and interim CEO Mani Mohindru, PhD, discussing onvansertib clinical data and its potential role in mCRC management.
Cardiff Oncology (Nasdaq: CRDF) will present new preclinical data on its oral PLK1 inhibitor onvansertib at the AACR Annual Meeting 2026 in San Diego.
The poster (Abstract 329) shows onvansertib enhanced antitumor activity and reversed resistance to trastuzumab deruxtecan (T-DXd) in therapy-resistant HER2-low breast cancer models. Presentation: April 19, 2026, 2:00 PM–5:00 PM PT. The poster will be posted to the company’s Scientific Publications page after the session.
Cardiff Oncology (Nasdaq: CRDF) announced that management will participate in three investor conferences in March 2026: TD Cowen on 03/04/26, Barclays on 03/10/26 and Leerink Partners on 03/11/26. Interested parties can view live webcasts and replays via the company’s Events page.
Cardiff Oncology (Nasdaq: CRDF) reported positive Phase 2 CRDF-004 results in first-line RAS-mutated metastatic colorectal cancer and provided full-year 2025 financials and a business update.
The 30 mg onvansertib + FOLFIRI/bev arm achieved a confirmed ORR of 72.2% versus 43.2% for combined SoC, and showed improved PFS (HR: 0.37, p<0.05). The company held $58.3M cash, expecting runway into Q1 2027, and named an interim CEO while searching for permanent CEO and CFO.
Cardiff Oncology (Nasdaq: CRDF) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference in a virtual format on February 25-26, 2026.
Interim CEO Mani Mohindru, PhD will present on 02/25/2026 at 1:20 PM ET. Management will hold 1x1 investor meetings. According to the company, a live webcast and replay will be available via the Events section of the Cardiff Oncology website.
Cardiff Oncology (NASDAQ: CRDF) reported positive Phase 2 CRDF-004 results for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC). In an intent-to-treat analysis (data cut Jan 22, 2026) the 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a confirmed objective response rate of 72.2% versus 43.2% for pooled standard of care, and a PFS hazard ratio 0.37 vs SoC (p=0.048) with median PFS not reached versus 10.97 months for SoC. Safety was manageable with no major additive toxicity. The company selected the 30 mg dose for a planned registrational program and expects final data and registrational plans in H1 2026.